7STAR 7-Hydroxy 60mg
The 7STAR 7‑Hydroxy 60mg 12pk 5ct is a retail display box of 7‑hydroxymitragynine extract tablets tailored for adult extract retailers, smoke shops, and specialty counter merchandising. Each display box contains 12 sealed blister packs, with 5 chewable tablets per pack, delivering a total of 60 tablets — each labeled to contain 60mg of 7‑hydroxymitragynine, a concentrated alkaloid derived from Mitragyna speciosa formulated for consistent strength and fast‑acting performance.
Retail packaging clearly displays tablet strength, pack count, and total tablet count per display box to support accurate SKU identification, merchandising, and shelf placement, making it a standardized option for experienced adult extract users in retail settings.
Key Benefits
• Retail‑Ready Display Box — Twelve blister packs with five tablets each make stocking and shelf presentation straightforward.
• Standardized 60 mg Strength — Each tablet delivers a predictable dose of 7‑hydroxymitragynine for consistent effects.
• Precision Dosing — Pre‑measured chewable tablets provide dependable intake with no measuring or mixing.
• Compact Blister Format — Blister packs are suitable for peg hooks, counter racks, or shelving without repackaging.
• Flavor & Format Flexibility — Often available in classic or fruit‑inspired profiles under the 7STAR brand.
Ingredients & Details
• Active Ingredient: 7‑hydroxymitragynine extract — 60 mg per chewable tablet.
• Inactive Ingredients: Typical tablet excipients to support chewable format and stability.
• Retail Pack Format: 5 tablets per sealed blister pack with strength and count clearly printed.
• Display Configuration: 12 packs per display box, totaling 60 tablets.
• Packaging: Branded retail units designed to support point‑of‑sale display, inventory tracking, and merchandising.
WARNING
• 21+ only — adult use only
• High‑potency extract product
• Keep out of reach of children and pets
• For retail sale and display only
• Comply with local and state regulations
Note: Products containing concentrated 7‑hydroxymitragynine are not FDA‑approved and may pose health risks, including opioid‑like effects. Legal status and retail eligibility vary by jurisdiction; retailers and consumers are responsible for complying with applicable laws and regulations.